Institutional
Remedium Capital Partners, LLC
CIK 0002104501
$281.2M
Reported AUM
6
Positions
Q1 2026
Period
2026-05-19
Filed
Editorial summary
Summary for Remedium Capital Partners, LLC · Q1 2026 is not yet generated. It will appear here after the next nightly run.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics Inc | $60.14 | -3.44% | 378.06% | 194.89% | $76.8M | 27.31% | +13,247 | +0.9% |
| 2 | SYRE | Spyre Therapeutics Inc | $73.65 | -6.15% | 334.00% | -51.94% | $73.5M | 26.13% | — | HELD |
| 3 | DMRA | Damora Therapeutics Inc | $21.01 | -5.83% | 538.60% | -80.41% | $53.0M | 18.84% | +1,925,000 | +1597.9% |
| 4 | APGE | Apogee Therapeutics Inc | $86.92 | -4.38% | 112.10% | 278.90% | $49.1M | 17.47% | — | HELD |
| 5 | JBIO | Jade Biosciences Inc | $16.94 | -4.51% | 135.61% | -96.13% | $22.2M | 7.88% | — | HELD |
| 6 | — | Crescent Biopharma Inc | — | — | — | — | $6.6M | 2.36% | — | HELD |
Source: SEC EDGAR · accession 0002104501-26-000010. 13F discloses long positions only — shorts, foreign equities, and options are excluded.